The International Society of Uterus Transplantation joins TTS as an Official Section

Click here to visit the ISUTx homepage to view welcome videos from Jiri Fronek (ISUTx President), Stefan G. Tullius (ISUTx Vice-President), and Mats Brannstrom (ISUTx Past-President).

We are delighted to announce that the International Society of Uterus Transplantation (ISUTx) will be joining The Transplantation Society as its tenth official Section.

Jiri Fronek

President, ISUTx

Marcelo Cantarovich

President, TTS

This is a significant milestone for both organizations. The pioneering field of uterus transplantation offers many challenges to those involved, and, as with all TTS Sections, TTS is committed to providing ISUTx the support it needs to address these challenges, while gaining expertise and insight in a critical field which has been underrepresented in TTS.

We believe that this partnership will be mutually beneficial to both Societies, and we look forward to collaborating on various projects, meetings and initiatives. We eagerly anticipate working together to share knowledge and experiences to benefit the members of both Societies. Over the coming months, we will explore opportunities and elaborate plans to create synergies between our Societies. This partnership is an exciting opportunity for all of us, and we look forward to our growing collaboration.

If you would like to know more about the Section, please reach out to Katie Tait, our Section Manager at TTS (

For more information on becoming a member of ISUTx, please contact Jennifer Varga, TTS Membership Coordinator (

Transplantation Direct July 2021 Issue


The July issue of Transplantation Direct is online. We have a number of articles related to kidney transplantation, including an analysis of how different types of allograft inflammation (biopsy) influence outcome, and on how induction therapy choice effects outcomes based on recipient age. Donor tubular cell loss is evaluated as a predictor of DGF, and combined urine microRNA and chemokine profiling is used to determine transplant rejection. There is a report on the reliability of interrater scoring of Karnofsky Performance Status (frailty) in waitlisted patients, and on a comprehensive characterization of cholesterol embolization syndrome as a cause of transplant failure. On the topic of COVID-19, there is an interesting survey supported by the National Kidney Foundation on attitudes of U.S. kidney transplant recipients regarding SARS-Cov-2 vaccination. Turning to other organ transplants, machine perfusion is tested in a combined human liver and lung transplant using organs from a DCD donor, and experimentally, whole blood is used in a pig DCD model studying particularly effects on the metabolic profile. Also in liver transplantation, there is an investigation of root causes of death in cases of portopulmonary hypertension, and results from a prospective randomized trial looking at the effects of everolimus on kidney function are presented. Another study reports on how HLA-DR matching and immunosuppression choice in patients of the Black race are associated with recurrence of autoimmune hepatitis post-liver transplantation. Encouraging results are also presented on liver transplant recipients co-infected with HIV and HCV in the current era of DAA therapy. Please visit our open access Transplantation Direct website for full details.


Matthew Cooper to Lead UNOS Board of Directors   

Matthew Cooper (TTS & IPITA Member), and Nationally Renowned Transplant Surgeon, to Lead United Network for Organ Sharing Board of Directors.

Matthew Cooper

Director of Kidney and Pancreas Transplantation at MedStar Georgetown Transplant Institute

Washington, DC (July 1, 2021) – Matthew Cooper, M.D., FACS, Director of Kidney and Pancreas Transplantation at MedStar Georgetown Transplant Institute at MedStar Georgetown University Hospital today begins his term as president of the United Network for Organ Sharing (UNOS) Board of Directors. UNOS is the mission-driven nonprofit serving as the nation’s transplant system. Last year the national transplant system set a record for the most lives saved by deceased organ donors.

“During the ongoing global health emergency, we are reminded again and again just how important organ donation and transplantation are to patients, families, and communities,” said Dr. Cooper. “I am eager to work alongside the UNOS board, colleagues, physicians, policymakers and members of the community to improve and expand equitable access to this lifesaving care.”

Since 2004, Dr. Cooper has been closely involved with UNOS, serving as a representative on the Living Donor Committee, and later as Vice Chair and then Chair of that committee. In 2012, he began a 2-year period of elected service on the UNOS Board. He has served on the inaugural Kidney Paired Donation (KPD) subcommittee, the Policy Oversight Committee, the Membership and Professional Affairs Committee and as co-chair of the Ad-hoc Systems Performance Workgroup, among other roles.

“We are excited to have Dr. Cooper as the new president of the UNOS Board of Directors,” said UNOS CEO Brian Shepard. “His record of service to the transplant community, innovative work at the Medstar Georgetown Transplant Institute, and ongoing advocacy for patients will help move UNOS and the donation and transplant community forward over the coming year.”

Dr. Cooper has devoted his career to advancing the field of organ transplant and to advocating for transplant patients and those in need of transplant. In addition to his service to UNOS, his leadership has included elected and volunteer positions with other leading transplant organizations, including the National Kidney Foundation(board member), Donate Life America (board member), The American Foundation for Donation and Transplant (president), and the American Society of Transplant Surgeons (councilor).

At MedStar Health, the Washington, DC region’s leading health care system, Dr. Cooper has led the kidney and pancreas transplant program at the MedStar Georgetown Transplant Institute since 2012. He has guided the program to national prominence, developing it into what is now the leading kidney transplant program in the Washington, DC region. Under his leadership, the program is among the top 10 highest volume centers for kidney transplants and the second largest paired kidney exchange program (through the National Kidney Registry) in the country; and is among the top three programs by volume for pancreas. In addition, Dr. Cooper provided critical testimony before the Subcommittee on Health of the Committee on Energy and Commerce in support of H.R. 5534 regarding the “Comprehensive Immunosuppressive Drug Coverage for the Kidney Transplant Patient’s Act” during the hearing on Legislation to Improve American’s Health Care Coverage and Outcomes. The legislation, which ensures life-long coverage for lifesaving immunosuppressants for transplant patients, became law in 2021.

Dr. Cooper received his medical degree from the Georgetown University School of Medicine in 1994, where he also currently Professor of Surgery. He completed his general surgery training at the Medical College of Wisconsin, followed by a fellowship in multi-organ abdominal transplantation in 2002 at the Johns Hopkins Hospital in Baltimore, Maryland. After director positions at both Johns Hopkins Hospital and the University of Maryland, he assumed his current role in Washington, DC in 2012.

Upcoming and Recent Webinars 

Thursday, July 22, 2021 - 10:00 AM (Local time in Montreal)
Local time (Corresponding local time at your current location)

Session 1 - In Your Local Time: Local time
Session 2 - In Your Local Time: Local time

TTS and WIT are hosting two networking discussion sessions lead by TTS Education Committee Members and WIT Members. Clips from the documentary will be shown and discussed as well as key themes that came out of the movie.

Registrants will have the ability to ask questions and interact with each other. Whether you will be joining for your morning coffee or pre/post dinner drinks, the session will be lively and interactive. Even if you are unable to watch the movie prior to the session, you are encouraged to register and join.

How to watch the documentary first
Registrants will have the ability to watch the documentary "Picture a Scientist" for two weeks prior to the discussion session and 1 week following the discussion session. The link will be provided after signup.
Women in Transplantation is delighted to announce two symposia as part of the 2021 CAST Virtual Congress, July 25-28.
Access to the Women in Transplantation symposia is FREE to WIT members.

Symposium 1 (click for details)
Symposium 1 - In Your Local Time: Local time
  • Dr. Vathsala Anantharam - Equity in donors and recipients in places with disparities
  • Dr. Germaine Wong - Equity in leadership
  • Dr. Maggie Ma - Fertility and pregnancy post solid organ transplantation
  • Dr. Lkhaakhuu Od-Erdene - How women can bring change to organ transplantation – the Mongolian experience

Symposium 2 (click for details)
Symposium 2 - In Your Local Time: Local time
  • Dr. Allison Tong, Dr. Nicole Scholes-Robertson and Dr. Amanda Dominello - Gender balance in living donation – from the recipient and donor perspective
  • Dr. Vasanthi Ramesh - Sex disparities in access to transplantation care during COVID-19 in Asia
  • Dr. Deirdre Sawinski - Fertility and pregnancy post solid organ transplantation
  • This session will be followed by a 30 minute panel discussion.

Newsletter - July 2021

In this newsletter we highlight recent awards & achievements of DICG current and past leadership, a publication co-authored by a member of the DICG council, current events as well as other important topics.

And, in case you missed it in April, 2021 we launched the DICG Course on Ethical Issues in Transplantation and The Declaration of Istanbul.

ISODP Journal Watch - Issue 2 - July 2021

In this second ‘Journal Watch’ Newsletter, we highlight eight recent publications in deceased organ donation of special interest to the donation

TTS Masterclasses: Immunosuppression Series July 9, 12 & 14

Delivered by the world’s best known and regional experts, each Masterclass includes presentations by an international and a regional expert to bring perspective to the topic, highlight differences and opportunities, and bolster active discussions.

Hot Off The Press 


Selected Publications by TTS Education Committee. This week's selection made by Drs. Enver Akalin and Marlies Reinders

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals

Alison Tarke et al.
Cell Reports Medicine (2021), DOI:
The emergence of SARS-CoV-2 variants with evidence of antibody escape highlight the importance of addressing whether the total CD4+ and CD8+ T cell recognition is also affected. Tis study compared SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. The total reactivity against SARS-CoV-2 variants is similar in terms of magnitude and frequency of response, with decreases in the 10 to 22% range observed. A total of 7% and 3% of previously identified CD4+ and CD8+ T cell epitopes, respectively, are impacted by mutations in the various VOCs. Thus, SARS-CoV-2 variants analyzed herein do not majorly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution.

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group;
JAMA. 2021 Jul 6. doi: 10.1001/jama.2021.11330
A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P = .003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P < .001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P = .52) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16).

A Systematic Review and Meta-analysis of COVID-19 in Kidney Transplant Recipients: Lessons to be Learned

Daan Kremer et al.
Am J Transplant. 2021 Jul 1. doi: 10.1111/ajt.16742.
This study included 74 studies with 5,559 KTR with COVID-19 (64.0% males, mean age 58.2 years, mean 73 months after transplantation) in total. The risk of mortality, 23% (95%CI: 21%-27%), and AKI, 50% (95%CI: 44%-56%), is high among KTR with COVID-19, regardless of sex, age and comorbidities.

In the News 



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6